The increase in adiponectin expression and plasma levels with drugs already existing or with novel therapeutic strategies is therefore considered valuable in the prevention and treatment of obesity-related metabolic and cardiovascular diseases in humans. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.